Financial News
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
May 05, 2023 at 10:49 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
--News Direct--
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ: TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/tiziana-life-sciences-expansion-into-new-clinical-indications-proactive-research-analyst-254277864
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View More
Whitbread H1 Earnings Call Highlights ↗
Today 7:02 EDT
What Bellway (BWY) Said on Its H2 Earnings Call ↗
Today 7:02 EDT
What PageGroup (PAGE) Said on Its Q3 Earnings Call ↗
Today 5:02 EDT
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
